Erasca, Inc. 10-Q

Item 5 . Other Information. Effective as of May 15, 2023, David Chacko, M.D., currently the Company’s Chief Financial Officer has been promoted to the dual position of Chief Financial Officer and Chief Business Officer of the Company. Effective as of May 15, 2023, Nicholas (Nik) Chetwyn, Ph.D., has been promoted to the position of Chief Operating Officer of the Company. Dr. Chetwyn, age 53, joined the Company in March 2021 as Senior Vice President of Operations. Dr. Chetwyn brings over 25 years of experience in drug development in the pharmaceutical industry. Prior to joining the Company, since October 2018, Dr. Chetwyn has been the co-founder and president of MindScienceConnection, Inc., a strategy and leadership development company that focused on partnering with biopharmaceutical companies to navigate the unique challenges of building and maintaining thriving research cultures while developing the scientific leaders and executives of the future. Prior to MindScienceConnection, from June 2006 to October 2018, Dr. Chetwyn was an executive at Genentech, Inc. in Small Molecule Drug Discovery where he helped build the small molecule drug development organization, helped drive the significant expansion of technical and drug manufacturing capabilities, served on multiple governance committees, was a technical development team leader for a small molecule inhibitor of AKT, and represented Genentech on the board of directors for the Allotrope Foundation. While at Genentech, Nik supported new drug application (NDA) filings for ERIVEDGE and COTELLIC. Prior to Genentech, from February 2002 to April 2006, Dr. Chetwyn was an Associate Director at Pfizer Inc. (Global R&D) (NYSE: PFE) and also served as a pharmaceutical sciences team leader (PSTL) for a small molecule oncology project. Prior to Pfizer, Dr. Chetwyn held roles of increasing responsibility at GSK plc (formerly known as GlaxoSmithKline plc) where he was involved in the development of multiple small-molecule oncology candidates, new technology development and supplemental new drug application (sNDA) filings for WELLBUTRIN. Dr. Chetwyn earned a M.S. and Ph.D. in pharmaceutical chemistry from the University of Kansas and a B.Sc. in chemical and pharmaceutical sciences from the University of Sunderland. 33 Item 6. Exhibits. Exhibit Number Exhibit Description Incorporated by Reference Filed Herewith Form Date Number 3.1 Amended and Restated Certificate of Incorporation of Erasca, Inc. 8-K 7/20/2021 3.1 3.2 Amended and Restated Bylaws of Erasca, Inc. 8-K 7/20/2021 3.2 4.1 Specimen stock certificate evidencing the shares of common stock S-1 6/25/2021 4.1 4.2 Amended and Restated Stockholders Agreement, dated April 15, 2020, by and among the Registrant and certain of its stockholders S-1 6/25/2021 4.2 31.1 Certification of Chief Executive Officer of Erasca, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 X 31.2 Certification of Chief Financial Officer of Erasca, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 X 32.1* Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 X 32.2* Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 X 101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. X 101.SCH Inline XBRL Taxonomy Extension Schema Document X 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document X 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document X 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document X 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document X 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) X * This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act. 34 SIG NATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Erasca, Inc. Date: May 15, 2023 By: /s/ Jonathan E. Lim M.D. Jonathan E. Lim, M.D. Chairman, Chief Executive Officer and Co-Founder (Principal Executive Officer) Date: May 15, 2023 By: /s/ David M. Chacko, M.D. David M. Chacko, M.D. Chief Financial Officer (Principal Financial and Accounting Officer) 35